# Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

> **NCT06161818** · PHASE2 · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 216 (estimated)

## Conditions studied

- Esophageal Cancer
- Adenocarcinoma of the Esophagus

## Interventions

- **DRUG:** FLOT-CROSS or CROSS-FLOT

## Key facts

- **NCT ID:** NCT06161818
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-12
- **Primary completion:** 2029-09-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161818, "Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06161818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*